Last Price$29.80.3%
Market Cap$13.0B
LTM Net Debt
$2,702.0M
YoY Growth
+7.1%
3Y CAGR
+34.8%
5Y CAGR
+10.9%
Stock quality & Intrinsic value
6/10
132.9% undervalued
Smith & Nephew plc Net Debt
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Debt | $287.0M | ($212.0M) | $1,308.0M | $1,328.0M | $970.0M | $492.0M | $138.0M | $290.0M | $254.0M | $1,612.0M | $1,360.0M | $1,551.0M | $1,283.0M | $1,103.0M | $1,770.0M | $1,928.0M | $2,049.0M | $2,522.0M | $2,782.0M | $2,702.0M |
Overvalued or undervalued?
Check the intrinsic value for SNN
and see if it's the right time to invest.
Smith & Nephew plc (SNN) Net Debt comparison analysis
General
LTM Net Debt
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Smith & Nephew plcSNN
$2,702.0M
7.1%
34.8%
10.9%
Median Peer Set
$5,550.5M
(6.0%)
(1.2%)
2.9%
Medtronic plcMDT
$18.7B
10.8%
10.3%
4.5%
Boston Scientific CorporationBSX
$10.7B
24.4%
12.5%
1.3%
Stryker CorporationSYK
$9,195.0M
(11.9%)
(2.4%)
5.5%
Abbott LaboratoriesABT
$7,054.0M
(15.5%)
(7.8%)
(14.0%)
Zimmer Biomet Holdings, Inc.ZBH
$5,679.1M
1.2%
(5.3%)
(6.3%)
Koninklijke Philips N.V.PHG
$5,421.8M
(14.4%)
3.9%
5.4%
STERIS plcSTE
$2,132.3M
(35.6%)
(12.1%)
15.0%
DexCom, Inc.DXCM
($50.5M)
(61.2%)
(55.5%)
(33.0%)
Insulet CorporationPODD
($869.6M)
N/A
N/A
N/A
Edwards Lifesciences CorporationEW
($3,275.9M)
254.3%
61.6%
31.3%
SNN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 2,552.0 6.6% | 2,779.0 8.9% | 3,369.0 21.2% | 3,801.0 12.8% | 3,772.0 (0.8%) | 3,962.0 5.0% | 4,270.0 7.8% | 4,137.0 (3.1%) | 4,351.0 5.2% | 4,617.0 6.1% | 4,634.0 0.4% | 4,669.0 0.8% | 4,765.0 2.1% | 4,904.0 2.9% | 5,138.0 4.8% | 4,560.0 (11.2%) | 5,212.0 14.3% | 5,215.0 0.1% | 5,549.0 6.4% | 5,810.0 4.7% |
| Cost of Goods Sold (COGS) | 701.0 | 769.0 | 994.0 | 1,077.0 | 1,030.0 | 1,031.0 | 1,140.0 | 1,070.0 | 1,100.0 | 1,162.0 | 1,143.0 | 1,272.0 | 1,248.0 | 1,298.0 | 1,338.0 | 1,396.0 | 1,543.0 | 1,540.0 | 1,730.0 | 1,764.0 |
% margin | 1,851.0 72.5% | 2,010.0 72.3% | 2,375.0 70.5% | 2,724.0 71.7% | 2,742.0 72.7% | 2,931.0 74.0% | 3,130.0 73.3% | 3,067.0 74.1% | 3,251.0 74.7% | 3,455.0 74.8% | 3,491.0 75.3% | 3,397.0 72.8% | 3,517.0 73.8% | 3,606.0 73.5% | 3,800.0 74.0% | 3,164.0 69.4% | 3,669.0 70.4% | 3,675.0 70.5% | 3,819.0 68.8% | 4,046.0 69.6% |
| Operating Expenses | 1,345.0 | 1,453.0 | 1,766.0 | 2,080.0 | 2,019.0 | 2,011.0 | 2,268.0 | 2,221.0 | 2,441.0 | 2,706.0 | 2,863.0 | 2,596.0 | 2,583.0 | 2,743.0 | 2,985.0 | 2,869.0 | 3,076.0 | 3,225.0 | 3,394.0 | 3,389.0 |
| Research & Development Expenses (R&D) | 122.0 | 120.0 | 142.0 | 152.0 | 155.0 | 151.0 | 167.0 | 171.0 | 231.0 | 235.0 | 222.0 | 230.0 | 223.0 | 246.0 | 292.0 | 307.0 | 356.0 | 345.0 | 299.0 | 289.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,212.0 | 1,319.0 | 1,530.0 | 1,796.0 | 1,864.0 | 1,860.0 | 2,101.0 | 2,050.0 | 2,210.0 | 2,471.0 | 2,641.0 | 2,366.0 | 2,360.0 | 2,497.0 | 2,693.0 | 2,562.0 | 2,720.0 | 2,880.0 | 2,890.0 | 3,100.0 |
% margin | 422.0 16.5% | 537.0 19.3% | 493.0 14.6% | 630.0 16.6% | 723.0 19.2% | 920.0 23.2% | 862.0 20.2% | 846.0 20.4% | 810.0 18.6% | 749.0 16.2% | 628.0 13.6% | 801.0 17.2% | 934.0 19.6% | 863.0 17.6% | 815.0 15.9% | 295.0 6.5% | 593.0 11.4% | 315.0 6.0% | 425.0 7.7% | 657.0 11.3% |
| Interest Income | 27.0 | 19.0 | 10.0 | 5.0 | 2.0 | 3.0 | 4.0 | 11.0 | 14.0 | 13.0 | 11.0 | 6.0 | 6.0 | 8.0 | 10.0 | 6.0 | 6.0 | 14.0 | 34.0 | 0.0 |
| Interest Expense | 18.0 | 9.0 | 40.0 | 71.0 | 42.0 | 18.0 | 12.0 | 9.0 | 10.0 | 35.0 | 49.0 | 52.0 | 57.0 | 59.0 | 65.0 | 62.0 | 80.0 | 80.0 | 139.0 | 0.0 |
| Pre-tax Income | 428.0 | 550.0 | 469.0 | 564.0 | 670.0 | 895.0 | 848.0 | 1,100.0 | 802.0 | 714.0 | 559.0 | 1,062.0 | 879.0 | 781.0 | 743.0 | 246.0 | 586.0 | 235.0 | 290.0 | 498.0 |
% effective tax rate | 126.0 29.4% | 156.0 28.4% | 153.0 32.6% | 187.0 33.2% | 198.0 29.6% | 280.0 31.3% | 266.0 31.4% | 371.0 33.7% | 246.0 30.7% | 213.0 29.8% | 149.0 26.7% | 278.0 26.2% | 112.0 12.7% | 118.0 15.1% | 143.0 19.2% | (202.0) (82.1%) | 62.0 10.6% | 12.0 5.1% | 27.0 9.3% | 86.0 17.3% |
% margin | 333.0 13.0% | 745.0 26.8% | 316.0 9.4% | 377.0 9.9% | 472.0 12.5% | 615.0 15.5% | 582.0 13.6% | 729.0 17.6% | 556.0 12.8% | 501.0 10.9% | 410.0 8.8% | 784.0 16.8% | 767.0 16.1% | 663.0 13.5% | 600.0 11.7% | 448.0 9.8% | 524.0 10.1% | 223.0 4.3% | 263.0 4.7% | 412.0 7.1% |
| EPS | 0.36 | 0.79 | 0.34 | 0.43 | 0.53 | 0.69 | 0.65 | 0.81 | 0.62 | 0.56 | 0.46 | 0.88 | 0.88 | 0.76 | 0.69 | 0.51 | 0.60 | 0.25 | 0.60 | 0.47 |
| Diluted EPS | 0.35 | 0.79 | 0.34 | 0.42 | 0.53 | 0.69 | 0.65 | 0.81 | 0.61 | 0.56 | 0.46 | 0.88 | 0.88 | 0.76 | 0.68 | 0.51 | 0.60 | 0.25 | 0.60 | 0.47 |
% margin | 683.0 26.8% | 703.0 25.3% | 721.0 21.4% | 910.0 23.9% | 1,039.0 27.5% | 1,211.0 30.6% | 1,164.0 27.3% | 1,182.0 28.6% | 1,184.0 27.2% | 1,186.0 25.7% | 1,115.0 24.1% | 1,266.0 27.1% | 1,393.0 29.2% | 1,287.0 26.2% | 1,320.0 25.7% | 866.0 19.0% | 1,242.0 23.8% | 943.0 18.1% | 979.0 17.6% | 1,237.0 21.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Smith & Nephew plc's Net Debt?
As of today, Smith & Nephew plc's last 12-month Net Debt is $2,702.0M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Smith & Nephew plc's Net Debt growth rate?
Over the last year, Smith & Nephew plc's Net Debt growth was 7.1%. The average annual Net Debt growth rates for Smith & Nephew plc have been 28.2% over the past three years, 10.9% over the past five years.
3) Is Smith & Nephew plc's Net Debt growth rate Good?
Over the last year, Smith & Nephew plc's Net Debt growth was 7.1%, which is higher than industry growth of 0.5%. It indicates that Smith & Nephew plc's Net Debt growth is Bad.